SOTAX Group to Acquire Majority Stake in Ortiv-Q3
Mumbai: The SOTAX Group (SOTAX) and Ortiv-Q3
(Ortiv) are pleased to announce their collaboration to further enhance their
capabilities in the field of Pharma Services. Through a majority investment
into the equity of Ortiv, SOTAX not only strengthens its reach to a major
geographic area but also gains access to new technical capabilities and
resources that are built up within Ortiv. Ortiv through this joint venture
strengthens its position to grow and perform over average and gains access to
the global commercial network of SOTAX.
New
premises of 10.000 sqft (around 1.000 m2), will be set up in the forthcoming
months in Ahmedabad, India, a brand-new, state-of-the-art infrastructure
including modern workspace and set of latest instruments to perform cGMP
analytical services with a clear focus on complex dosage forms characterization
and proof of concept for formulations. The new infrastructure will facilitate
accelerating complex formulation development program of global clients and
shall work with high throughput to perform excellent services to our customers.
"With
this alliance, SOTAX continues to strengthen its leading position as a complete
solution provider in the global market and we are convinced that the adopted
strategy will be beneficial for all, our customers, Ortiv as well as SOTAX. We
are convinced that this will be a very fruitful collaboration” states Rolf
Benz, CEO, and President of the Board of SOTAX Group.
"We
are convinced that this collaboration will boost the success of Ortiv and will
lift the Company to the next level. We see huge potential in the field of
Pharma Services especially in the field of complex products in India and with
the investment of SOTAX into our company, we are convinced that this will be a
success story in the forthcoming years.” highlighted Pawan Gupta, Mukesh Kumar
and Sadhana Gupta co-founders of Ortiv.
"We
are pleased to bring all Ortiv-Q3 employees with their experience and their
innovative ideas on board and to further develop the business of our Pharma
Services division in order to continue to offer our customers best-in-class
services, with an extremely high level of expertise and quality" commented
Samir Haddouchi, Managing Director of SOTAX Pharma Services.
About SOTAX:
The
SOTAX Group is the leading global provider of complete testing solutions for
Research and Development (R&D), Quality Control (QC), and In-Process
Control (IPC) departments of the pharmaceutical industry. SOTAX’s instruments,
software, and services are recognized by their customers worldwide as the
industry benchmark for best-in-class solutions. It is also the only analytical
services supplier specialized in R&D for dissolution and release testing.
The company is offering a high level of expertise for complex dosage form
testing as well as an FDA-inspected facility for routine cGMP testing. Its
laboratories, located all over the globe, are operating for clients worldwide
ranging from virtual companies to big Pharma including generic.
About Ortiv-Q3:
The
Ortiv company, founded by enthusiastic and experienced pharma professionals,
provides a complete suite of drug release testing for a variety of dosage forms
ranging from simple tablets to complex formulations like microspheres,
suspensions, emulsions, nano-dispersions, liposomal and topical formulations.
Also, Ortiv provides in-vitro permeation studies for topical and solid orals.
The company is equipped with innovative and novel tools like microdialysis and
oral formulations permeation evaluation system, which can minimize the risk of
bio-failures.
Comments
Post a Comment